Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 19th World Nephrology Conference Singapore City, Singapore.

Day :

  • Pediatric Nephrology
Speaker
Biography:

Professor Boris Ajdinović, MD, PhD, civilian, nuclear medicine specialist, Since 2004. Head of The Institute of Nuclear Medicine at the Medical Military Academy (MMA); since 2011 the head of The Group of Diagnostic Institutes at the MMA; retired 2021.Was born 01.02.1954. in Vrginmost where finished basic school. High school and Medical University finished in Belgrade 1972/78.Nuclear medicine specialization finished 1984. since he is accepted on full time job in Institute of nuclear medicine MMA. Beside routine work, his work paricularry is applaying nuclear medicine methods in nephrourology.

Abstract:

The best approach to imaging of a child with febrile urinary tract infection (UTI) is highly debatable. Renal ultrasound (US), a voiding cystourethrogram (VCUG) and renal dimercaptosuccinic acid (DMSA) scintigraphy are the most commonly used imaging methods. UTI are common in childhood, and most children recover without complications. Use of imaging to check for abnormalities or complications therefore needs to be targeted carefully. Because a renal US is noninvasive and may give supplemental information about a child’s risk for lower tract infections by showing bladder abnormalities, a renal US should be initially ordered study in children with UTI. In 2011. The American Academy of Pediatric (AAP) recommended that renal US be performed after first febrile UTI but that VCUG should be obtained only if there are renal abnormalities, or after second febrile UTI. Significant controversy surrounded this recommendation and many pediatric urologists disagreed with the APP guidelines (Logvinenko T. et al., 2015., Bush NC et al., 2015.). Obtaining a VCUG with first UTI in all male patients, females younger than 3 years, children clinically suspected of having pyelonephritis, and those with US abnormalities has been recommended (”bottom-up” approach). 

  • Renal Dialysis
Biography:

Chun-Jung Chien majors in veterinary medicine at NPUST, after obtaining her DVM license, she continues her study for a master degree in the conservation reproductive biology and regenerative medicine lab at the graduate institute of Veterinary Medicine at National Taiwan University. Her research focuses on investigating the mechanism of peritoneal dialysis-induced fibrosis and exploring novel therapeutic approaches for peritoneal fibrosis.

 

Abstract:

Statement of the Problem: Peritoneal dialysis (PD) is one of the kidney replacement therapies that maintain the lives of patients with kidney failure. Long-term PD will lead to peritoneal fibrosis (PF), which would cause functional and morphologic changes in the peritoneum and eventually result in ultrafiltration failure. Despite efforts being made, there is still no effective treatment that has been developed to alleviate PF. Recently, an endoplasmic reticulum protein, thioredoxin domain-containing protein 5 (TXNDC5), was identified as a novel mediator in the process of organ fibrosis in multiple organs. The purpose of this study is to explore a potential target to treat ultrafiltration failure by investigating the role of TXNDC5 in PF. Methodology & Theoretical Orientation: A 5-week methylglyoxal (MGO)-induced peritoneal fibrosis mouse model was established, and the peritoneal tissue was harvested to validate the expression of fibrosis-related proteins and protein expression of TXNDC5 via western blot and immunofluorescence staining. Findings: Histological and Masson’s trichrome staining showed MGO-induced significant peritoneum thickening when compared with PD fluid control group, indicating that the PF was successfully established (Fig. 1). Immunofluorescent staining confirmed that an increased TXNDC5 signal was present at the thickened parietal peritoneum. In addition, western blot results showed that both TXNDC5 and fibrogenesis-related signaling were upregulated in MGO-induced peritoneum (Fig. 2). Using Col-GFP transgenic mice (Col1a1-GFPTg), we showed mesothelial cells became Col-GFP positive on the peritoneal surface, indicated that mesothelial cells expressed collagen I secreting ability after MGO-induction, and likely play a role in the progression of MGO-induced peritoneal fibrosis (Fig. 3). Conclusion & Significance: TXNDC5 protein expression is increased after MGO induction and is positively correlated with fibrogenesis-related signaling. Therefore, targeting TXNDC5 could be a potential therapeutic approach against the development of PD-induced PF, which may prolong the service life of PD patients. 

  • Nephrology and Therapeutics
Biography:

Marie Angeline J. Mora and Mariane Paula C. Agoncillo are both in their second year of residency in Internal Medicine at St. Luke’s Medical Center Quezon City. They both graduated from the same medical school at University of Santo Tomas in Manila. They are interested in the field of Nephrology, and together with their adviser and a nephrology specialist, Dr. Rachel Anne C. Siute, they have created this meta-analysis on Finerenone a reality.

Abstract:

Finerenone is a novel therapeutic option in patients with chronic kidney disease (CKD) explored in the study of FIDELIO-DKD wherein use of nonsteroidal mineralocorticoid receptor antagonists play a role in reducing proteinuria and preventing decline of estimated glomerular function rate (eGFR). However, application of this drug in the Nephrology community has been slow. This metaanalysis aims to evaluate the role of Finerenone in decreasing disease progression of CKD using five published Randomized Control Trials retrieved from PubMed, ClinicalTrials, and Google scholar utilizing the Chochrane risk of bias for quality assessment. With a confidence interval of 95%, forest plots were generated using the Revman Program. A pooled total of 14,973 patients were included in this study. The evidence suggests that finerenone has shown significant results with a primary outcome showing overall effect (0.86%, 95% CI [0.79 - 0.93] p = 0.0004, I2 = 0%) on CKD disease progression as well as preventing further increase in urine albumin-creatinine ratio (UACR) (-.0.29%, 95% CI [-0.32 to -0.27], p = <0.0001, I2 0%) favoring the use of finerenone. Among patients with CKD, use of finerenone compared to placebo delayed the decline in eGFR. Further studies are needed to evaluate the use of angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB), sodium-glucose cotransporter inhibitor (SGLT2) and other active medications in conjunction with finerenone.

  • Chronic and End Stage Renal Diseases